Caprock Group LLC Purchases 351 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Caprock Group LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,647 shares of the biopharmaceutical company’s stock after purchasing an additional 351 shares during the period. Caprock Group LLC’s holdings in Regeneron Pharmaceuticals were worth $1,173,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Mizuho Securities USA LLC increased its position in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after acquiring an additional 51,162 shares during the period. Principal Financial Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Simplify Asset Management Inc. raised its position in Regeneron Pharmaceuticals by 50.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth about $1,334,000. Finally, Daiwa Securities Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after buying an additional 2,234 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on REGN. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Finally, Sanford C. Bernstein decreased their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Trading Down 1.5 %

REGN opened at $672.98 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $73.95 billion, a PE ratio of 16.65, a P/E/G ratio of 1.62 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company’s 50-day moving average is $720.81 and its 200 day moving average is $922.87.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.